Genetic Profiteering: Scandal of firm ‘hiding vital breast cancer data’

| November 5, 2012 |
The company that makes the world's biggest-selling gene test for breast and ovarian cancers is refusing to share groundbreaking knowledge that could benefit patients, academics claim. Myriad Genetics is accused of deliberately withholding data that could help other scientists to understand cancer genetics, on the grounds that the information is commercially sensitive.

The company that makes the world’s biggest-selling gene test for breast and ovarian cancers is refusing to share groundbreaking knowledge that could benefit patients, academics claim. Myriad Genetics is accused of deliberately withholding data that could help other scientists to understand cancer genetics, on the grounds that the information is commercially sensitive.

View the original article here: Genetic Profiteering: Scandal of firm ‘hiding vital breast cancer data’